商品编号


AG-20B-0025-C100



品牌


Adipogen



公司


Adipogen



公司分类


Antibodies



Size

100 ?g


商品信息


More Information



Product Details



Synonyms

TRAIL Receptor 4; TRUNDD; DcR2; TNFRSF10D; CD264



Product Type

Monoclonal Antibody



Properties



Clone

HS402



Isotype

Mouse IgG1



Source/Host

Purified from concentrated hybridoma tissue culture supernatant.



Immunogen/Antigen

Recombinant human TRAIL-R4 (DcR2).



Application


Flow Cytometry

Immunocytochemistry

Immunohistochemistry:
(frozen sections)

Immunoprecipitation




Crossreactivity

Human



Specificity

Recognizes human TRAIL-R4. Does not cross-react with human TRAIL-R1, -R2 or -R3.



Purity

≥95% (SDS-PAGE)



Purity Detail

Protein G-affinity purified.



Concentration

1mg/ml



Formulation

Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





TRAIL-R4 is a receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.


Product References

TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol.
170,
1814 (2003)

TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood
103,
517 (2004)

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ.
11 Suppl 1,
S86 (2004)

cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem.
279,
52824 (2004)

Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood
111,
4780 (2008)